OCULAR HYPERTENSION - RISK FACTORS AND THERAPY?
Introduction/Aim: The goal of our study was to analyze the epidemiological`s characteristics of ocular hypertension, as well as the influence of chronic risk factors on glaucoma development (conversion in glaucoma). We tried to make some entries for solving this complex ophthalmological problem.
Material /Methods: From 2009 to 2015, a retrospective control study was performed on 121 patient with diagnoses of bilateral ocular hypertension and without disease progression/conversion of glaucoma (by standard protocols of diagnosis and basic procedures) on tertiary level at Clinic of Ophthalmology, Clinical Centre of Kragujevac, Serbia.. The authors analyzed epidemiological characteristics: sex, age groups, positive/negative family history and personal history with chronic risk factors (one and/or two) of ocular hypertension. The data obtained from this study were statistically analyzed in SPSS program, version 20.00.
Results: As for the patients, 69 of them (57.02%) were male and 52 female (42.98%). Dominant age group was between 40-49 (42.15%) and then group between 50-59 (40.50%) years of age. Anamnesis data indicated the absence of family anamnesis 71 (58.68%). Risk factors for ocular hypertension were presented in 103 (85.13%) patients, 18 of them (14.87%) did not respond. One risk factor - cardiovascular disease was noted in 83 (68.59%), with two risk factors - cardiovascular diseases and diabetes mellitus in 20 patients (16.53%) and with PEX syndroma at other respondents.
Conclusion: Ocular hypertension is not a common disease, but with risk factors, such as older age, positive family history, and chronic risk factors syndicated, represents a serious clinical and social problem, so the question remains for ophthalmologists - pro or against therapy? Those in favor of therapy would state the safety and protection from conversion/progression of glaucoma; but those against therapy would only mention adequate monitoring of patients.
Spe?kauskas M, Tamošiãnas A, Jaš¡inskas V. Association of ocular pseudoexfoliation syndrome with ischaemic heart disease, arterial hypertension and diabetes mellitus. Acta Ophthalmol. 2012; 90(6): 470-5.
Xu L, Wang YX, Jonas JB, Wang YS, Wang S. Ocular hypertension and diabetes mellitus in the Beijing Eye Study. J Glaucoma. 2009; 18(1): 21-5.
Pache M. Primary open-angle glaucoma and systemic diseases. Ophthalmologe. 2007; 104(5): 431-41.
Popa SA, Bucãtariu PM, Costin D, Manole A, Matei MC, Merchez M. Contributions to know the involvement of cardio-vascular diseases in glaucoma etiology, studied on a sample of 996 patients assisted in Clinic of Ophthalmology, "Prof. N. Oblu" Emergency Hospital, Iasi. Rev Med Chir Soc Med Nat Iasi. 2011; 115(1): 127-32.
Stefan C, Dumitrica DM, Dragomir L, Cristea I, Sapundgieva A. Ocular hypertension-follow up or treatment? Oftalmologia. 2009; 53(2): 23-5.
Henderson AD, Bruce BB, Newman NJ, Biousse V. Hypertension-related eye abnormalities and the risk of stroke. Rev Neurol Dis. 2011; 8(1-2): 1-9.
Tan GS, Wong TY, Fong CW, Aung T. Singapore Malay Eye Study. Diabetes, metabolic abnormalities and glaucoma. Arch Ophthalmol. 2009; 127(10): 1354-61.
Primus S, Harris A, Siesky BA, Guidoboni G. Diabetes: a risk factor for glaucoma? Br J Ophthalmol. 2011; 95(12): 1621-2.
Imai K, Hamaguchi M, Mori K, et al. Metabolic syndrome as a risk factor for high-ocular tension. Int J Obes (Lond). 2010; 34(7): 1209-17.
Zhao JL, Ge J, Li XX, et al. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol. 2011;11: 23.
Tzamalis A, Kynigopoulos M, Chalvatzis N, Dimitrakos S, Schlote T. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population. J Ocul Pharmacol Ther. 2013; 29(1): 41-7.
Swymer C, Neville MW. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2012; 46(11): 1506-10.
Apreutesei NA, Chiselita D, Motas OI. Glaucoma evolution in patients with diabetes. Rev Med Chir Soc Med Nat Iasi. 2014; 118(3): 667-74.
Chan PP, Leung CK, Chiu V, et al. Protocol-driven adjustment of ocular hypotensive medication in patients at low risk of conversion to glaucoma. Br J Ophthalmol. 2015; 99(9): 1245-50.
Medeiros FA, Weinreb RN, Zangwill LM, et al. Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology. 2008; 115(6): 934-40.
Starmer J. Arguments against pressure-lowering treatment of ocular hypertension. Prophylactic treatment is unnecessary. Ophthalmologe. 2011; 108(11): 1006-10.
Fechtner RD, Khouri AS. Evolving global risk assessment of ocular hypertension to glaucoma. Curr Opin Ophthalmol. 2007; 18(2): 104-9.
Lee BL, Wilson MR. Ocular Hypertension Treatment Study (OHTS) commentary. Curr Opin Ophthalmol. 2003; 14(2): 74-7.
Higginbotham EJ. Treating ocular hypertension to reduce glaucoma risk: when to treat? Drugs. 2006;66(8):1033-9.
Laplace O, Bron A, Nordmann JP. Management of ocular hypertension and chronic open-angle glaucoma by French ophthalmologists: the role of target intraocular pressure. J Fr Ophtalmol. 2006;29(4):353-8.
- There are currently no refbacks.
Copyright (c) 2016 SANAMED
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.